[The use of generic valparin xr in the treatment of epilepsy.].
Therapeutic efficacy of valparin xr, a new form of valproic acid (VPA) generic drugs, manufactured by "Torrent Pharmaceuticals Ltd", India, has been studied in 25 patients with epilepsy of different types and frequency of seizures. The therapeutic efficacy similar to that of an original VPA was determined in monotherapy strategy, being lower in polytherapy, but more effective than other antiepileptic treatment. As for original drugs, the best results were obtained for controlling myoclonic and polyclonic seizures. The percentage of side-effects did not exceed the same index for brand drugs. The substantial advantage of valparin xr is a lower price as compared to the original VPA.